4 minute read
January.17.2023
Many early-stage biotech companies struggle to find their way through the time period between initial scientific discovery and proof-of-concept human clinical trials, when funding sources are sparse. In this article for Bloomberg Law, Orrick’s Joseph Perkins and Stephen Thau explain how early-stage biotech startups can use decentralized autonomous organizations, or DAOs, to provide an alternative to traditional sources of capital.